Skip to content
Disclosery

BIOS Capital Management, LP

Follow

13F filer, CIK 1813845, Fort Worth, TX

BIOS Capital Management, LP reported $52,866,306 across 6 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001813845-26-000003

Period
2026-03-31
Reported value
$52.9M
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Part of the filer group BIOS Capital Management, LP

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RNTXadded+291,624$379K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LTRNreduced-145,072-$199K
INABreduced-85,612-$127K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001813845-26-000003, largest first. % of portfolio is the value over $52,866,306, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACTUACTUATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 9,893,651 shares; 2025Q1: 9,893,651 shares; 2025Q2: 9,965,079 shares; 2025Q3: 10,049,996 shares; 2025Q4: 10,049,996 shares; 2026Q1: 10,049,996 shares 10,049,996$27.5M52.09%0Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 995,249 shares; 2025Q1: 995,249 shares; 2025Q2: 3,683,429 shares; 2025Q3: 3,683,429 shares; 2025Q4: 3,683,429 shares; 2026Q1: 3,683,429 shares 3,683,429$16.8M31.7%0Timeline
CGTXCOGNITION THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,000,000 shares; 2025Q1: 6,000,000 shares; 2025Q2: 6,000,000 shares; 2025Q3: 6,000,000 shares; 2025Q4: 6,000,000 shares; 2026Q1: 6,000,000 shares 6,000,000$4.56M8.63%0Timeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,690,751 shares; 2025Q1: 1,690,751 shares; 2025Q2: 1,690,751 shares; 2025Q3: 1,690,751 shares; 2025Q4: 1,690,751 shares; 2026Q1: 1,982,375 shares 1,982,375$2.58M4.87%+291,624Timeline
LTRNLANTERN PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,207,709 shares; 2025Q1: 1,207,709 shares; 2025Q2: 1,075,952 shares; 2025Q3: 1,015,715 shares; 2025Q4: 1,009,507 shares; 2026Q1: 864,435 shares 864,435$1.18M2.24%-145,072Timeline
INABIN8BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 253,417 shares; 2026Q1: 167,805 shares 167,805$248K0.47%-85,612Timeline

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001813845-26-000003 base2026-05-13acceptance time not in the bulk data set